Biosero, Inc., developer of laboratory automation solutions to orchestrate scientific discoveries, announced the appointment of Daniel Schumann to the position of chief operations officer. Starting in April, Mr. Schumann will be responsible for overseeing all operational functions, including supply chain, procurement, integrations, engineering, project management, quality, and IT.
“With nearly two decades of experience in medical devices and life science instrumentation, Dan has the operational acumen and engineering background that will make him a perfect fit for Biosero,” said Ryan Bernhardt, CEO of Biosero. “I welcome Dan to our team as we look to streamline operations and improve scalability to better serve customers with our extensive lab automation solutions.”
Also Read: MOMA Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer
Prior to joining Biosero, Mr. Schumann served as vice president of operations at Becton, Dickinson and Company, where he led a center of excellence focusing on medical instrument manufacturing and new product introduction. Before that he worked in medical device engineering and manufacturing at Danaher/Invetech, BIT GmbH, and MediPhysics. Mr. Schumann’s career began in the automotive industry, where he worked as a design and manufacturing engineer at Ford Motor Company and as the marketing lead for the S-Type sedan at Jaguar Cars North America. He earned his bachelor’s degree in mechanical engineering at Harvard University, his MBA in marketing from the Kellogg School of Management at Northwestern University, and his master of engineering degree from Northwestern.
“It is truly an honor to join this talented team and to help Biosero bring its industry-leading automation technology to even more organizations and laboratories around the world,” said Mr. Schumann. “I’m excited about the prospect of driving on-site operations for our San Diego headquarters and I look forward to finding innovative ways to optimize processes and performance so we can help our customers develop life-saving therapies more quickly.”
SOURCE: BusinessWire